Published 12:25 IST, October 26th 2020
COVID-19: Israel to begin vaccine trials from Nov 1 after receiving regulatory approval
The IIBR will start human trials of its COVID-19 vaccine from November 1. The vaccine has already been tested on several ‘animal models’.
Advertisement
After receiving all required approvals from Ministry of Health and Helsinki Committee, Israeli Defence Ministry said that Israel Institute for Biological Research (IIBR) will start human trials of its coronavirus vaccine from vember 1. According to reports by PTI, committee is bound to ensure well being of all candidates involved in trials. Also, it will make sure that experiment is conducted with keeping all medical guidelines and ethics in mind. According to a tally by John Hopkins University, Israel has a total of 309,946 cases with 2,397 fatalities.
Israel plans vaccine trials
In mid-October, Israel planned to ease restrictions when Prime Minister Benjamin Netanyahu said that country is set to exit its second coronavirus lockdown, but this time "carefully and responsibly". country mand to contain breakdwon by sealing borders. human trials of vaccine candidate Brilife will involve around 30,000 candidates and is divided into three sts. vaccine is expected to come out for use only after mid 2021. According to reports by PTI, alternate Prime Minister-cum-Defence Minister Benny Gantz said, “This is a day of hope for citizens of Israel, thanks to IIBR researchers. Just two months ago I received first bottle of vaccine. Today we alrey have 25,000 vaccine doses and are starting next phase of test”. He thanked team of researchers and called m a ‘commando unit’ for paving way for ir citizens.
Advertisement
Gantz assured citizens that he, along with Israeli Government and Defence establishment will continue to provide support and resources which are required to establish a safe and efficient ‘blue and white vaccine’, referring to colours in flag and also name of his party. trial will begin with only 2 candidates, however, first phase will include multiple safety tests on 80 ‘healthy volunteers’. second phase will involve extensive safety tests on 960 healthy volunteers. third phase will check effectiveness of vaccine as it will include 30,000 volunteers.
Advertisement
vaccine has alrey been tested on several ‘animal models’. It was concluded that it h an effective immune response in small animals like mice, hamsters and rabbits, and also big animals like pigs. IIBR Director, Prof Shmuel Shapira said, “We are w beginning a crucial phase in development of vaccine -- clinical trials phase. I believe in abilities of our scientists and I am confident that we can produce a safe and effective vaccine”.
Advertisement
Advertisement
12:26 IST, October 26th 2020